B-NHL

Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma

11 drugs in development·8 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
CD19/CD22-CAR-transduced T cells	Filana Therapeutics Inc. (FLNA)

Phase 2(5)

Drug	Company
AUCATZYL/obe-cel	Autolus Therapeutics plc (AUTL)
bbt369	2seventy bio, Inc. (TSVT)
CLLS52	Cellectis S.A. (CLLS)
cnct19	CASI Pharmaceuticals, Inc (DE) (CASI)
UCART20x22	Cellectis S.A. (CLLS)

Phase 1(5)

Drug	Company
odronextamab	REGENERON PHARMACEUTICALS, INC. (REGN)
pit565	Novartis AG (NVS)
pit565	Novartis AG (NVS)
regn5837	REGENERON PHARMACEUTICALS, INC. (REGN)
vispa-cel	Caribou Biosciences, Inc. (CRBU)

BioSniper tracks 11 drugs in development for B-NHL across 8 companies.

There are 1 clinical trial targeting B-NHL tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.